Suppr超能文献

肌少性肥胖与2019冠状病毒病的住院或死亡风险:来自英国生物银行的研究结果。

Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank.

作者信息

Wilkinson Thomas J, Yates Thomas, Baker Luke A, Zaccardi Francesco, Smith Alice C

机构信息

Leicester Kidney Lifestyle Team, Department of Health Sciences University of Leicester Leicester UK.

Leicester NIHR Biomedical Research Centre Leicester UK.

出版信息

JCSM Rapid Commun. 2022 Jan-Jun;5(1):3-9. doi: 10.1002/rco2.47. Epub 2021 Jul 3.

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The role of skeletal muscle mass in modulating immune response is well documented. Whilst obesity is well established as a key factor in COVID-19 and outcome, no study has examined the influence of both sarcopenia (low muscle mass) and obesity, termed 'sarcopenic obesity' on the risk of severe COVID-19.

METHODS

This study uses data from UK Biobank. Probable sarcopenia was defined as low handgrip strength. Sarcopenic obesity was mutually exclusively defined as the presence of obesity and low muscle mass [based on two established criteria: appendicular lean mass (ALM) adjusted for either (i) height or (ii) body mass index]. Severe COVID-19 was defined by a positive severe acute respiratory syndrome coronavirus 2 test result in a hospital setting and/or death with a primary cause reported as COVID-19. Fully adjusted logistic regression models were used to analyse the associations between sarcopenic status and severe COVID-19. This work was conducted under UK Biobank Application Number 52553.

RESULTS

We analysed data from 490 301 UK Biobank participants (median age 70.0 years, 46% male); 2203 (0.4%) had severe COVID-19. Individuals with probable sarcopenia were 64% more likely to have had severe COVID-19 (odds ratio 1.638;  < 0.001). Obesity increased the likelihood of severe COVID-19 by 76% ( < 0.001). Using either ALM index or ALM/body mass index to define low muscle mass, those with sarcopenic obesity were 2.6 times more likely to have severe COVID-19 (odds ratio 2.619;  < 0.001). Sarcopenia alone did not increase the risk of COVID-19.

CONCLUSIONS

Sarcopenic obesity may increase the risk of severe COVID-19, over that of obesity alone. The mechanisms for this are complex but could be a result of a reduction in respiratory functioning, immune response, and ability to respond to metabolic stress.

摘要

背景

2019冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2引起的一种传染病。骨骼肌质量在调节免疫反应中的作用已有充分记录。虽然肥胖已被确认为COVID-19及其预后的一个关键因素,但尚无研究探讨肌肉减少症(低肌肉质量)和肥胖(即“肌少症肥胖”)对重症COVID-19风险的综合影响。

方法

本研究使用了英国生物银行的数据。可能的肌肉减少症定义为握力低。肌少症肥胖被相互排斥地定义为存在肥胖和低肌肉质量[基于两个既定标准:(i)根据身高或(ii)体重指数调整的四肢瘦体重(ALM)]。重症COVID-19定义为在医院环境中严重急性呼吸综合征冠状病毒2检测结果呈阳性和/或主要死因报告为COVID-19的死亡。使用完全调整的逻辑回归模型分析肌少症状态与重症COVID-19之间的关联。本研究是在英国生物银行申请号52553下进行的。

结果

我们分析了来自490301名英国生物银行参与者的数据(中位年龄70.0岁,46%为男性);2203人(0.4%)患有重症COVID-19。可能患有肌肉减少症的个体患重症COVID-19的可能性高出64%(比值比1.638;<0.001)。肥胖使重症COVID-19的可能性增加了76%(<0.001)。使用ALM指数或ALM/体重指数来定义低肌肉质量,患有肌少症肥胖的个体患重症COVID-19 的可能性高出2.6倍(比值比2.619;<0.001)。单纯的肌肉减少症不会增加COVID-19的风险。

结论

肌少症肥胖可能比单纯肥胖更易增加重症COVID-19的风险。其机制复杂,但可能是呼吸功能、免疫反应和应对代谢应激能力下降的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd16/8441916/f465a9951c32/RCO2-5-3-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验